Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer

Clinical Lung Cancer

Volumn 13, Issue 4, 2012, Pages 304-311

  Togashi, Yosuke ^a   Masago, Katsuhiro ^a   Handa, Tomohiro ^a   Tanizawa, Kiminobu ^a   Okuda, Chiyuki ^a   Sakamori, Yuichi ^a   Nagai, Hiroki ^a   Kim, Young Hak ^a   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute exacerbation; Chemotherapy; Idiopathic pulmonary fibrosis; Interstitial lung disease; Small cell lung cancer

Indexed keywords

ETOPOSIDE; IRINOTECAN; PLATINUM;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; JAPANESE; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; JAPAN; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; PNEUMONIA; PROGNOSIS; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

EID: 84861644056     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.11.001     Document Type: Article

References (31)

1. D.M. Jackman, B.E. Johnson Small-cell lung cancer Lancet 366 2005 1385 1396 (Pubitemid 41443406)
2. M. Puglisi, S. Dolly, A. Faria Treatment options for small cell lung cancer - do we have more choice? Br J Cancer 102 2010 629 638
3. I.K. Demedts, K.Y. Vermaelen, J.P. van Meerbeeck Treatment of extensive-stage small cell lung carcinoma: current status and future prospects Eur Respir J 35 2010 202 215
4. R. Hubbard, A. Venn, S. Lewis Lung cancer and cryptogenic fibrosing alveolitis A population-based cohort study Am J Respir Crit Care Med 161 2000 5 8 (Pubitemid 30055895)
5. J. Park, D.S. Kim, T.S. Shim Lung cancer in patients with idiopathic pulmonary fibrosis Eur Respir J 17 2001 1216 1219 (Pubitemid 32717481)
6. J.M. Harris, I.D. Johnston, R. Rudd Cryptogenic fibrosing alveolitis and lung cancer: the BTS study Thorax 65 2010 70 76
7. European Respiratory Society; American Thoracic Society American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS Board of Directors, June 2001 and by the ERS Executive Committee, June 2001 Erratum in Am J Respir Crit Care Med 166 2002 426
8. H.R. Collard, B.B. Moore, K.R. Flaherty Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators Acute exacerbations of idiopathic pulmonary fibrosis Am J Respir Crit Care Med 176 2007 636 643 (Pubitemid 47503070)
9. Y. Kondoh, H. Taniguchi, Y. Kawabata Acute exacerbation in idiopathic pulmonary fibrosis Analysis of clinical and pathologic findings in three cases Chest 103 1993 1808 1812 (Pubitemid 23174318)
10. R. Hyzy, S. Huang, J. Myers Acute exacerbation of idiopathic pulmonary fibrosis Chest 132 2007 1652 1658 (Pubitemid 350156025)
11. I.C. Papanikolaou, F. Drakopanagiotakis, V.S. Polychronopoulos Acute exacerbations of interstitial lung diseases Curr Opin Pulm Med 16 2010 480 486
12. Y. Minegishi, K. Takenaka, H. Mizutani Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy Intern Med 48 2009 665 672
13. T. Shukuya, T. Ishiwata, M. Hara Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease Anticancer Res 30 2010 4357 4361
14. Y. Minegishi, H. Kuribayashi, K. Kitamura The feasibility study of carboplatin plus etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias J Thorac Oncol 6 2011 801 807
15. Y. Minegishi, J. Sudoh, H. Kuribayasi The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias Lung Cancer 71 2011 70 74
16. P. Therasse, S.G. Arbuck, E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
17. M. Akira, H. Hamada, M. Sakatani CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis AJR Am J Roentgenol 168 1997 79 83 (Pubitemid 27014751)
18. T. Makimoto, S. Tsuchiya, K. Hayakawa Risk factors for severe radiation pneumonitis in lung cancer Jpn J Clin Oncol 29 1999 192 197
19. Y. Ohe, S. Yamamoto, K. Suzuki Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer Eur J Cancer 37 2001 54 63 (Pubitemid 32119360)
20. S. Kudoh, H. Kato, Y. Nishiwaki Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study Am J Respir Crit Care Med 177 2008 1348 1357 (Pubitemid 351860912)
21. S. Sundstrom, R.M. Bremnes, S. Kaasa Norwegian Lung Cancer Study Group Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up J Clin Oncol 20 2002 4665 4672 (Pubitemid 36025283)
22. K. Noda, Y. Nishiwaki, M. Kawahara Japan Clinical Oncology Group Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer N Engl J Med 346 2002 85 91 (Pubitemid 34438898)
23. J.P. Lima, L.V. dos Santos, E.C. Sasse Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis J Thorac Oncol 5 2010 1986 1997
24. Y. Madarnas, P. Webster, A.M. Shorter Irinotecan-associated pulmonary toxicity Anticancer Drugs 11 2000 709 713
25. O. Michielin, E. Udry, D. Périard Irinotecan-induced interstitial pneumonia Lancet Oncol 5 2004 322 324 (Pubitemid 38541585)
26. S. Onoda, N. Masuda, T. Seto Thoracic Oncology Research Group Study 0301 Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301 J Clin Oncol 24 2006 5448 5453 (Pubitemid 46623179)
27. A. Inoue, S. Sugawara, K. Yamazaki Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402 J Clin Oncol 26 2008 5401 5406
28. K. Yoh, H. Kenmotsu, Y. Yamaguchi Severe interstitial lung disease associated with amrubicin treatment J Thorac Oncol 5 2010 1435 1438
29. T. Fukui, S. Otani, R. Hataishi Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease Cancer Chemother Pharmacol 65 2010 803 806
30. M. Takeda, I. Okamoto, C. Makimura Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease J Thorac Oncol 5 2010 1103 1104
31. S.C. Chang, C.Y. Chang, C.Y. Chen Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia J Thorac Oncol 5 2010 1105 1106